XTLB - XTL Biopharmaceuticals, Ltd. Analyst Forecast Prices
This daily price chart for XTL Biopharmaceuticals (XTLB) reflects the price action of an asset valued at 6.01. XTL Biopharmaceuticals (XTLB) relies on strict control over biomaterial delivery to ensure trial purity. The business focuses on developing myeloma therapies for patients with resistant blood cancer, while capital stability depends on R&D success and FDA verdicts regarding systemic lupus erythematosus drugs.
Analytical breakdowns for XTL Biopharmaceuticals, Ltd. (XTLB)
- stock price and consensus target price:
- market capitalization statistics:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity XTL Biopharmaceuticals|XTLB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital XTL Bio|XTLB - Company Aggregate Debts|Debts to Book Capitalization XTL Biopharmaceuticals, Ltd.|XTLB - Company Long-Term Debt|Company Short-Term Loans and Borrowings XTL Biopharmaceuticals|Quick Liquidity Indicator xtlbio.com
- financial results and valuation multiples details:
XTLB - Net Profit|Projected Future Earnings XTL Biopharmaceuticals|XTLB - Price to Earnings Ratio|Future Price to Earnings Multiple XTL Biopharmaceuticals Ltd|XTLB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio XTL Biopharmaceuticals, Ltd.|XTLB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months XTL Biopharmaceuticals|XTLB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months xtlbio.com|XTLB - Net earnings per share growth this year|Earnings growth forecast for next year XTL Biopharmaceuticals
General company analysis:XTLB xtlbio.com
XTL Biopharmaceuticals' development of targeted therapies for autoimmune diseases requires colossal R&D expenditures, making the stock price dependent on scientific breakthroughs. The current value of 6.01 reflects a weighted average assessment from investment houses aggregating professional fair value forecasts; by analyzing the overall consensus valuation of the security, an investor can promptly adjust their portfolio, given the high volatility of the biopharmaceutical sector.
Competitors of XTL Biopharmaceuticals
argenx.com - Broker Consensus Forecast|BioNTech - Consensus Target|Analyst Forecast Prices ABVX (Abivax SA)|ADMA - Price Target Chart|PTGX: Price Target Chart|IMVT: Analyst Consensus Forecast|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO: Consensus Target|ACRS (Aclaris Therapeutics, Inc) - Broker Consensus Forecast|KYTX (Kyverna Therapeutics) - Consensus Target|TLSA: Analyst Forecast Prices|Price Target Chart Cabaletta Bio|Price Target Chart VTYX|Consensus Target THTX (Theratechnologies Inc)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|Analyst Median Target zurabio.com ZURA|aTyr (ATYR) - Price Target Chart|Average Forecast Price Adagene Inc. (ADAG)|Price Target Chart ImageneBio|Shattuck Therapeutics - Forecast Levels Chart|Analyst Consensus Forecast EQ|CNTB (connectbiopharm.com) - Fair Value Consensus|Analyst Consensus Forecast IMUX (Immunic)|Analyst Consensus Forecast Atara Biotherapeutics, Inc. ATRA|IFRX - Price Target Chart|Fair Value Consensus XFOR (x4pharma.com)|adicetbio.com (ACET) - Price Target Chart|Consensus Target Celularity|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Analyst Consensus Forecast KZR|Consensus Target sabbiotherapeutics.com SABS|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Average Forecast Price|QTTB: Consensus Target|GOVX - Analyst Consensus Forecast|EDSA (Edesa Biotech, Inc.) - Consensus Target|IBIO: Analyst Forecast Prices|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI - Price Target Chart|XRTX: Price Target Chart|ReShape Lifesciences (HIND) - Price Target Chart|REVB - Analyst Median Target|Consensus Target INDP|Broker Consensus Forecast SCNI (scinai.com)|Consensus Target CALI (CalciMedica, Inc.)|Analyst Forecast Prices AFMD|Price Target Chart Allakos ALLK|HOOKIPA Pharma, Inc. - Price Target Chart|IGM Bio - Analyst Consensus Forecast|ITOS: Price Target Chart|Ocean Biomedical (OCEA) - Price Target Chart|Forecast Levels Chart TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
